奥曲肽治疗化学疗法导致的腹泻直肠癌病人一篇综述（翻译）.docVIP

Octreotide in chemotherapy induced diarrhoea in colorectal cancer: a review article 奥曲肽治疗化学疗法导致的腹泻直肠癌病人：一篇综述 Abstract摘要 Background: Chemotherapy-induced diarrhea(CID)is well known in cancer management. The risk is greater when the primary cancer is colorectal. The article aims towards assessing the role of octreotide in CID through an extensive literature search. 背景：化学疗法导致的腹泻(CID)在癌症治疗中比较常见。当原发癌是直肠癌时风险更大。这篇综述的目的在于通过大量广泛的文献调查评价奥曲肽在治疗CID的作用。 Methods：After searching through PBMED,MEDLINE and the Cochrane library, only those studies which were published over the last 20 years in English and where at least the majority of the cohort were colorectal patients, were included. Two randomized trials, four non-randomized studies and two case-series publications were thus considered. 方法：在通过PUBMED,MEDLIN和循证医学文库搜索之后，仅挑选出在近20年用英文发表的，并且所选的队列为结肠病人的研究论文。两个随机对比临床试验，四个非随机研究和两案例系列出版物在考虑的范围之内。 Results: It was seen in both the randomized studies, that octreotide had much better outcome as compared to loperamide in treating severe CID. Among 88 patients from the non-randomized studies with severe CID, the primary cancer was colorectal in 79 patients.61 patients had drug-resistant CID. Within a maximum of 96 hours, octreotide reduced CID by ≥ 2 grades in 91% of 88 patients and in 88.52% patients with drug-resistant CID. 效果：从两个随机研究中都可以看出，在治疗严重的CID时，奥曲肽比咯哌丁胺有更好的笑料。在从非随机法选择的88个病人中，原发癌是结肠癌的有79个病人。61个病人有CID抗药性。在最多96个小时内，奥曲肽降低了88个患者中的91%的患者，CID抗药性患者中的88.52%患者至少两级。 Conclusion: Octreotide is effective in treating severe CID, resistant to other modes of treatment. It is associated with a few minor adverse effects. Though expensive, octreotide could be considered as first line medication in CID of grades 3 or above. Its use in lower grades of CID would not be cost effective. 结论：奥曲肽在治疗严重的CID患者比较有效，能抵抗其他方式的治疗，且不良反应较少。尽管价格比较昂贵，奥曲肽 Key words: octreotide, chemotherapy induced diarrhoea, octreotide in diarrhoea. 关键词：奥曲肽，化学疗法导致的腹泻， Abbreviations缩写 CID = Chemotherapy induced diarrhoea化学疗法诱导的腹泻 5FU = 5 Fluoro